Bcl‑2 family: Novel insight into individualized therapy for ovarian cancer (Review)
- Authors:
- Jing Yuan
- Hua Lan
- Xiaoyan Jiang
- Da Zeng
- Songshu Xiao
-
Affiliations: Department of Gynecology and Obstetrics, Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China - Published online on: July 29, 2020 https://doi.org/10.3892/ijmm.2020.4689
- Pages: 1255-1265
-
Copyright: © Yuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Webb PM and Jordan SJ: Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 41:3–14. 2017. View Article : Google Scholar | |
|
Davis A, Tinker AV and Friedlander M: 'Platinum resistant' ovarian cancer: What is it, who to treat and how to measure benefit? Gynecol Oncol. 133:624–631. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
International Collaborative Ovarian and Neoplasm Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet. 360:505–515. 2002. View Article : Google Scholar | |
|
Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis-Kyriakou N, Ryan JE, Sheriff M, Rassy E and Pavlidis N: Veliparib in ovarian cancer: A new synthetically lethal therapeutic approach. Invest New Drugs. 38:181–193. 2020. View Article : Google Scholar | |
|
Markman M: Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am. 17:957–968. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Bast RC Jr, Hennessy B and Mills GB: The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N; Australian Ovarian Cancer Study Group; Harnett PR, Bowtell DDL and DeFazio A: Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol. 150:239–246. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis Primers. 2:160612016. View Article : Google Scholar : PubMed/NCBI | |
|
Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et al: Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 15:668–679. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xie H, Wang W, Xia B, Jin W and Lou G: Therapeutic applications of PARP inhibitors in ovarian cancer. Biomed Pharmacother. 127:1102042020. View Article : Google Scholar : PubMed/NCBI | |
|
Boussios S, Karihtala P, Moschetta M, Karathanasi A, Sadauskaite A, Rassy E and Pavlidis N: Combined strategies with poly (ADP-Ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: A literature review. Diagnostics (Basel). 9:872019. View Article : Google Scholar | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Matsuura K, Huang NJ, Cocce K, Zhang L and Kornbluth S: Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin. Oncogene. 36:1698–1706. 2017. View Article : Google Scholar : | |
|
Fernald K and Kurokawa M: Evading apoptosis in cancer. Trends Cell Biol. 23:620–633. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hassan M, Watari H, AbuAlmaaty A, Ohba Y and Sakuragi N: Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014:1508452014. View Article : Google Scholar : PubMed/NCBI | |
|
Valentin R, Grabow S and Davids MS: The rise of apoptosis: Targeting apoptosis in hematologic malignancies. Blood. 132:1248–1264. 2018. View Article : Google Scholar | |
|
Kerr JF, Wyllie AH and Currie AR: Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 26:239–257. 1972. View Article : Google Scholar : PubMed/NCBI | |
|
Chung C: Restoring the switch for cancer cell death: Targeting the apoptosis signaling pathway. Am J Health Syst Pharm. 75:945–952. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Green DR and Llambi F: Cell death signaling. Cold Spring Harb Perspect Biol. 7:a0060802015. View Article : Google Scholar : PubMed/NCBI | |
|
Martinvalet D: Mitochondrial entry of cytotoxic proteases: A new insight into the granzyme B cell death pathway. Oxid Med Cell Longev. 2019:91652142019. View Article : Google Scholar : PubMed/NCBI | |
|
Solano-Gálvez SG, Abadi-Chiriti J, Gutiérrez-Velez L, Rodríguez-Puente E, Konstat-Korzenny E, Álvarez-Hernández DA, Franyuti-Kelly G, Gutiérrez-Kobeh L and Vázquez-López R: Apoptosis: Activation and inhibition in health and disease. Med Sci (Basel). 6. pp. 542018 | |
|
Shamas-Din A, Kale J, Leber B and Andrews DW: Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol. 5:a87142013. View Article : Google Scholar | |
|
Caria S, Hinds MG and Kvansakul M: Structural insight into an evolutionarily ancient programmed cell death regulator- the crystal structure of marine sponge BHP2 bound to LB-Bak-2. Cell Death Dis. 8:e25432017. View Article : Google Scholar | |
|
Kvansakul M and Hinds MG: The Bcl-2 family: Structures, interactions and targets for drug discovery. Apoptosis. 20:136–150. 2015. View Article : Google Scholar | |
|
Banjara S, Suraweera CD, Hinds MG and Kvansakul M: The Bcl-2 family: Ancient origins, conserved structures, and diver-gent mechanisms. Biomolecules. 10:1282020. View Article : Google Scholar | |
|
Kvansakul M and Hinds MG: The structural biology of BH3-only proteins. Methods Enzymol. 544:49–74. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Huang DC and Strasser A: BH3-Only proteins-essential initiators of apoptotic cell death. Cell. 103:839–842. 2000. View Article : Google Scholar | |
|
Elkholi R, Renault TT, Serasinghe MN and Chipuk JE: Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy? Cancer Metab. 2:162014. View Article : Google Scholar | |
|
Adams CM, Clark-Garvey S, Porcu P and Eischen CM: Targeting the Bcl-2 family in B cell lymphoma. Front Oncol. 8:6362019. View Article : Google Scholar : PubMed/NCBI | |
|
Estaquier J, Vallette F, Vayssiere JL and Mignotte B: The mitochondrial pathways of apoptosis. Adv Exp Med Biol. 942:157–183. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Martinou JC and Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S and Korsmeyer SJ: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2:183–192. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Mérino D, Giam M, Hughes PD, Siggs OM, Heger K, O'Reilly LA, Adams JM, Strasser A, Lee EF, Fairlie WD and Bouillet P: The role of BH3-only protein bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol. 186:355–362. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L, Flanagan A, Andrews DW, Sorger P and Letai A: BID prefer-entially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell. 51:751–765. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T and Korsmeyer SJ: BAX and BAK regulation of endoplasmic reticulum Ca2+: A control point for apoptosis. Science. 300:135–139. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Große L, Wurm CA, Brüser C, Neumann D, Jans DC and Jakobs S: Bax assembles into large ring-like structures remodeling the mitochondrial outer membrane in apoptosis. EMBO J. 35:402–413. 2016. View Article : Google Scholar | |
|
Salvador-Gallego R, Mund M, Cosentino K, Schneider J, Unsay J, Schraermeyer U, Engelhardt J, Ries J and García-Sáez AJ: Bax assembly into rings and arcs in apoptotic mitochondria is linked to membrane pores. EMBO J. 35:389–401. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Smaili SS, Hsu YT, Youle RJ and Russell JT: Mitochondria in Ca2+ signaling and apoptosis. J Bioenerg Biomembr. 32:35–46. 2000. View Article : Google Scholar | |
|
van Zyl B, Tang D and Bowden NA: Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment. Endocr Relat Cancer. 25:R303–R318. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Larson CA, Blair BG, Safaei R and Howell SB: The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol. 75:324–330. 2009. View Article : Google Scholar : | |
|
Pan H, Kim E, Rankin GO, Rojanasakul Y, Tu Y and Chen YC: Theaflavin-3,3'-digallate enhances the inhibitory effect of cisplatin by regulating the copper transporter 1 and glutathione in human ovarian cancer cells. Int J Mol Sci. 19:1172018. View Article : Google Scholar | |
|
Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:293–299. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Conacci-Sorrell M, McFerrin L and Eisenman RN: An overview of MYC and its interactome. Cold Spring Harb Perspect Med. 4:a143572014. View Article : Google Scholar | |
|
Cao X, Bennett RL and May WS: c-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis. J Biol Chem. 283:14490–14496. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hahne JC, Honig A, Meyer SR, Gambaryan S, Walter U, Wischhusen J, Häussler SF, Segerer SE, Fujita N, Dietl J and Engel JB: Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. Oncol Rep. 28:2023–2028. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cheaib B, Auguste A and Leary A: The PI3K/Akt/mTOR pathway in ovarian cancer: Therapeutic opportunities and challenges. Chin J Cancer. 34:4–16. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cardenas C, Montagna MK, Pitruzzello M, Lima E, Mor G and Alvero AB: Adipocyte microenvironment promotes Bclxl expression and confers chemoresistance in ovarian cancer cells. Apoptosis. 22:558–569. 2017. View Article : Google Scholar | |
|
Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 26:1324–1337. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Leibowitz B and Yu J: Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther. 9:417–422. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Beale PJ, Rogers P, Boxall F, Sharp SY and Kelland LR: BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer. 82:436–440. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Marx D and Meden H: Differential expression of apoptosis-associated genes Bax and Bcl-2 in ovarian cancer. Methods Mol Med. 39:687–691. 2001.PubMed/NCBI | |
|
Fauvet R, Dufournet C, Poncelet C, Uzan C, Hugol D and Daraï E: Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (Bcl-2 and Bcl-x) proteins in serous versus mucinous borderline ovarian tumours. J Surg Oncol. 92:337–343. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG and Rollason TP: P53 and bcl-2 assessment in serous ovarian carcinoma. Int J Gynecol Cancer. 18:241–248. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chaudhry P, Srinivasan R and Patel FD: Expression of the major fas family and Bcl-2 family of proteins in epithelial ovarian cancer (EOC) and their correlation to chemotherapeutic response and outcome. Oncol Res. 18:549–559. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Binju M, Amaya-Padilla MA, Wan G, Gunosewoyo H, Suryo Rahmanto Y and Yu Y: Therapeutic inducers of apoptosis in ovarian cancer. Cancers (Basel). 11:17862019. View Article : Google Scholar | |
|
Liang M and Zhao J: Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis. Eur Rev Med Pharmacol Sci. 22:5134–5139. 2018.PubMed/NCBI | |
|
Yang Y, Li S, Sun Y, Zhang D, Zhao Z and Liu L: Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2. Onco Targets Ther. 12:897–906. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al: SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 471:104–109. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Luo Q, Zhao P, Chang W, Wang Y, Shu T, Ding F, Li B and Liu Z: MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. Proc Natl Acad Sci USA. 116:2961–2966. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Zhang M, Jing Y, Yin X, Ma P, Zhang Z, Wang X, Di W and Zhuang G: Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 9:2152018. View Article : Google Scholar : PubMed/NCBI | |
|
Habata S, Iwasaki M, Sugio A, Suzuki M, Tamate M, Satohisa S, Tanaka R and Saito T: BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer. Int J Oncol. 49:402–410. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bonnefond ML, Lambert B, Giffard F, Abeilard E, Brotin E, Louis MH, Gueye MS, Gauduchon P, Poulain L and N'Diaye M: Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation. Apoptosis. 20:535–550. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu JR, Fletcher B, Page C, Hu C, Nunez G and Baker V: Bcl-xL is expressed in ovarian carcinoma and modulates chemo-therapy-induced apoptosis. Gynecol Oncol. 70:398–403. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M, Berger A and Carew JS: Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res. 19:3577–3590. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao XY, Liu L, Deng HX, Li J, Nie CL and Wei YQ: The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1. Mol Med. 17:1262–1274. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Dai Y, Zhao XJ, Li F, Yuan Y, Yan DM, Cao H, Huang XY, Hu Z, Ma D and Gao QL: Truncated Bid regulates cisplatin response via activation of mitochondrial apoptosis pathway in ovarian cancer. Hum Gene Ther. 31:325–338. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yamaguchi H, Bhalla K and Wang HG: Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. Cancer Res. 63:1483–1489. 2003.PubMed/NCBI | |
|
Kale J, Kutuk O, Brito GC, Andrews TS, Leber B, Letai A and Andrews DW: Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep. 19:e452352018. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Wang J, Zhou Y, Wang Y, Wang S and Zhang W: Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells. Cancer Lett. 321:137–143. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Huang X, Lin T, Gu J, Zhang L, Roth JA, Stephens LC, Yu Y, Liu J and Fang B: Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther. 9:1379–1386. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Tai YT, Lee S, Niloff E, Weisman C, Strobel T and Cannistra SA: BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol. 16:2583–2590. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Lauterwasser J, Todt F, Zerbes RM, Nguyen TN, Craigen W, Lazarou M, van der Laan M and Edlich F: The porin VDAC2 is the mitochondrial platform for Bax retrotranslocation. Sci Rep. 6:329942016. View Article : Google Scholar : PubMed/NCBI | |
|
Edlich F: BCL-2 proteins and apoptosis: Recent insights and unknowns. Biochem Biophys Res Commun. 500:26–34. 2018. View Article : Google Scholar | |
|
Lazarou M, Stojanovski D, Frazier AE, Kotevski A, Dewson G, Craigen WJ, Kluck RM, Vaux DL and Ryan MT: Inhibition of Bak activation by VDAC2 is dependent on the Bak transmembrane anchor. J Biol Chem. 285:36876–36883. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shoshan-Barmatz V, Keinan N and Zaid H: Uncovering the role of VDAC in the regulation of cell life and death. J Bioenerg Biomembr. 40:183–191. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shimizu S, Narita M and Tsujimoto Y: Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 399:483–487. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Boulikas T and Vougiouka M: Cisplatin and platinum drugs at the molecular level (Review). Oncol Rep. 10:1663–1682. 2003.PubMed/NCBI | |
|
Li J, Lee B and Lee AS: Endoplasmic reticulum stress-induced apoptosis: Multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem. 281:7260–7270. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Campbell KJ and Tait S: Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 8:1800022018. View Article : Google Scholar : PubMed/NCBI | |
|
Edlich F, Banerjee S, Suzuki M, Cleland MM, Arnoult D, Wang C, Neutzner A, Tjandra N and Youle RJ: Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell. 145:104–116. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Delbridge AR and Strasser A: The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 22:1071–1080. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Billard C: BH3 mimetics: Status of the field and new developments. Mol Cancer Ther. 12:1691–1700. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Gao W, Zhang Y, Wu S, Liu Y, Deng X, Xie L, Yang J, Yu H, Su J and Sun L: ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells. Int J Oncol. 53:1055–1068. 2018.PubMed/NCBI | |
|
Dai Y, Jin S, Li X and Wang D: The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer. Oncotarget. 8:1354–1368. 2017. View Article : Google Scholar : | |
|
Yu Y, Xu L, Qi L, Wang C, Xu N, Liu S, Li S, Tian H, Liu W, Xu Y and Li Z: ABT737 induces mitochondrial pathway apoptosis and mitophagy by regulating DRP1-dependent mitochondrial fission in human ovarian cancer cells. Biomed Pharmacother. 96:22–29. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xie Q, Su J, Jiao B, Shen L, Ma L, Qu X, Yu C, Jiang X, Xu Y and Sun L: ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells. Int J Oncol. 49:2507–2519. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A, et al: Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: An ex vivo experiment in human serous ovarian carcinoma. Int J Cancer. 136:E340–E350. 2015. View Article : Google Scholar | |
|
Stamelos VA, Robinson E, Redman CW and Richardson A: Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells. Gynecol Oncol. 128:377–382. 2013. View Article : Google Scholar | |
|
Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al: ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68:3421–3428. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wong M, Tan N, Zha J, Peale FV, Yue P, Fairbrother WJ and Belmont LD: Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Mol Cancer Ther. 11:1026–1035. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yokoyama T, Kohn EC, Brill E and Lee JM: Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP. Int J Oncol. 50:1064–1074. 2017. View Article : Google Scholar : | |
|
Iavarone C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Leverson JD, et al: Combined MEK and BCL-2/XL inhibition is effective in high-grade serous ovarian cancer patient-derived xenograft models and bim levels are predictive of responsiveness. Mol Cancer Ther. 18:642–655. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, et al: Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11:1149–1159. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q, Ji M, Pienta K, Lawrence T and Xu L: Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther. 7:2192–2202. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hu W, Wang F, Tang J, Liu X, Yuan Z, Nie C and Wei Y: Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101. J Biol Chem. 287:68–80. 2012. View Article : Google Scholar : | |
|
Karaca B, Atmaca H, Bozkurt E, Kisim A, Uzunoglu S, Karabulut B, Sezgin C, Sanli UA and Uslu R: Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells. Mol Biol Rep. 40:3925–3933. 2013. View Article : Google Scholar | |
|
Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, Maïga S, Béné MC, Moreau P, Pellat-Deceunynck C and Amiot M: The Bcl-2 specific BH3 mimetic ABT-199: A promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 28:210–212. 2014. View Article : Google Scholar : | |
|
Song T, Zhang M, Liu P, Xue Z, Fan Y and Zhang Z: Identification of JNK1 as a predicting biomarker for ABT-199 and paclitaxel combination treatment. Biochem Pharmacol. 155:102–109. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Abed MN, Abdullah MI and Richardson A: Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J Ovarian Res. 9:252016. View Article : Google Scholar : PubMed/NCBI | |
|
Yamaguchi R, Lartigue L and Perkins G: Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Pharmacol Ther. 195:13–20. 2019. View Article : Google Scholar | |
|
Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Toumelin-Braizat GL, Chanrion M, Kelly GL, Gong JN, Moujalled DM, et al: The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 538:477–482. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Zhang Z, Wei X and Dai R: Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and enhances cisplatin-induced apoptosis in ovarian cancer cells. J Ovarian Res. 8:32015. View Article : Google Scholar : PubMed/NCBI | |
|
Deng J: How to unleash mitochondrial apoptotic blockades to kill cancers? Acta Pharm Sin B. 7:18–26. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA and Letai A: Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 9:351–365. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, et al: Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 160:977–989. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim H, Tu HC, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJD and Cheng EHY: Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell. 36:487–499. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M and Letai A: BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 12:171–185. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ryan J and Letai A: BH3 profiling in whole cells by fluorimeter or FACS. Methods. 61:156–164. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Elefantova K, Lakatos B, Kubickova J, Sulova Z and Breier A: Detection of the mitochondrial membrane potential by the cationic dye JC-1 in L1210 cells with massive overexpression of the plasma membrane ABCB1 drug transporter. Int J Mol Sci. 19:19852018. View Article : Google Scholar : | |
|
Ryan J, Montero J, Rocco J and Letai A: iBH3: Simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 397:671–678. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Del Gaizo Moore V and Letai A: rofiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 332:202–205. 2013. View Article : Google Scholar | |
|
Montero J and Letai A: Dynamic BH3 profiling-poking cancer cells with a stick. Mol Cell Oncol. 3:e10401442016. View Article : Google Scholar : PubMed/NCBI | |
|
Ni CT, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Del Gaizo Moore V, Deng J, Anderson KC, Richardson P, Tai YT, et al: Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 334:1129–1133. 2011. View Article : Google Scholar | |
|
Paudel I, Hernandez SM, Portalatin GM, Chambers TP and Chambers JW: Sab concentrations indicate chemotherapeutic susceptibility in ovarian cancer cell lines. Biochem J. 475:3471–3492. 2018. View Article : Google Scholar : PubMed/NCBI |
